News

Discover ImmuSmol’s story, featured in the 2015 winter edition of the European Biotechnology Magazine.

Just a few words to thank our clients and partners and wish them a bright and joyful 2015.

ImmuSmol is pleased to announce it has raised 500 000 € to progress its monoclonal antibodies for cancer immunotherapy to in vivo proof-of-concept (POC).

Access latest article by ImmuSmol CEO Alban Bessède

NEW! ImmuSmol releases rabbit polyclonal antibodies against Tryptophan / Kynurenine metabolites, all validated for IHC in human samples.

Picture: L-Kynurenine detection by IHC in human colorectal cancer tissue using anti-L-Kynurenine rabbit pAb.

ImmuSmol will be in Turin for Bioeurope Spring 2014, on March 10-12. Contact us to arrange a meeting!

A short overview of ImmuSmol’s services for the development of antibodies against small molecules, and their subsequent validation for small molecule detection by ELISA or IHC.

Small molecule antibodies constitute a powerful alternative to mass spec and aptamer-based technologies for small molecule detection, building on the advantages of existing immunodetection methods such as ELISA and IHC. Overview…

A brief overview of ImmuSmol’s antibody development services for the detection of small molecules in biological samples…